• Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) reported an earnings per share (EPS) of -$0.24, missing the estimated EPS of $0.11, indicating ongoing financial challenges.
• Aurora's actual revenue of approximately $63.3 million was below the estimated $88.9 million.

Aurora Cannabis Inc. (NASDAQ: ACB, TSX: ACB) is a leading global medical cannabis company based in Canada. It focuses on producing and distributing medical cannabis products worldwide. Aurora competes with other major players in the cannabis industry, such as Tilray and Canopy Growth. Despite facing challenges, Aurora is making strides towards profitability through strategic shifts and financial management.

On June 18, 2025, Aurora reported an earnings per share (EPS) of -$0.24, missing the estimated EPS of $0.11. Aurora's actual revenue of approximately $63.3 million was below the estimated $88.9 million.

Aurora's financial metrics reveal a mixed picture. The company has a price-to-earnings (P/E) ratio of approximately 41.17, indicating investor confidence in its future earnings potential. However, the enterprise value to operating cash flow ratio is negative at -40.01, suggesting challenges in generating positive cash flow from operations. Despite this, Aurora maintains a strong liquidity position with a current ratio of 3.30, indicating its ability to meet short-term obligations.